Liquidia FY2028 EPS Estimate Increased by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at HC Wainwright boosted their FY2028 earnings per share estimates for shares of Liquidia in a report released on Tuesday, May 12th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $6.37 for the year, up from their prior estimate of $5.93. HC Wainwright currently has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.14 per share. HC Wainwright also issued estimates for Liquidia’s FY2030 earnings at $8.36 EPS.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 81.61% and a net margin of 7.74%.The company’s revenue was up 4187.1% on a year-over-year basis.

Other analysts have also issued reports about the stock. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Oppenheimer lifted their price target on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research note on Thursday, March 12th. BTIG Research lifted their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.33.

Liquidia Stock Performance

Shares of LQDA stock opened at $56.60 on Wednesday. The company has a 50 day moving average price of $38.17 and a 200-day moving average price of $35.29. Liquidia has a 52 week low of $11.85 and a 52 week high of $57.00. The firm has a market capitalization of $5.03 billion, a PE ratio of 404.31 and a beta of 0.41. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 32,744 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $38.37, for a total value of $1,256,387.28. Following the transaction, the chief executive officer owned 1,137,599 shares of the company’s stock, valued at approximately $43,649,673.63. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 62,550 shares of the firm’s stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $35.94, for a total transaction of $2,248,047.00. Following the completion of the transaction, the director directly owned 2,188,935 shares in the company, valued at approximately $78,670,323.90. The trade was a 2.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 653,820 shares of company stock valued at $25,838,508. 25.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Liquidia

Several large investors have recently added to or reduced their stakes in LQDA. Farallon Capital Management LLC lifted its holdings in Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after purchasing an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC purchased a new position in Liquidia during the third quarter valued at approximately $38,887,000. Caprock Group LLC purchased a new position in Liquidia during the third quarter valued at approximately $37,114,000. MPM Bioimpact LLC lifted its holdings in Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after purchasing an additional 1,200,869 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in Liquidia during the third quarter valued at approximately $12,571,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported a major Q1 beat, with EPS of $0.52 versus $0.41 expected and revenue of $132.87 million versus $119.44 million expected, reinforcing the company’s rapid commercial growth and improving profitability. Earnings report
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and projected at least $1 billion in net revenue by 2027, signaling strong launch momentum and a long growth runway. Seeking Alpha article
• Positive Sentiment: Needham raised its price target to $70 and BTIG lifted its target to $59, both keeping bullish ratings in place, which suggests Wall Street sees more upside after the earnings beat. Needham price target note
• Positive Sentiment: Zacks added Liquidia to its Strong Buy list, adding another sentiment boost following the earnings release. Zacks Strong Buy list
• Neutral Sentiment: CEO Roger Jeffs sold 25,000 shares in a pre-arranged 10b5-1 plan; while this is worth noting, it appears routine and relatively small versus his remaining stake. SEC filing
• Negative Sentiment: One recent downgrade argued that YUTREPIA’s launch momentum may be approaching a ceiling, raising questions about how much additional market-share expansion remains. Seeking Alpha downgrade

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).